NPR Examines New Study Looking At Risks, Benefits Of HIV Treatment Linked To Possible Fatal Birth Defects

NPR: A Promising Anti-HIV Drug Poses A Dilemma
“…[A new study published this month in the Annals of Internal Medicine] estimated what could happen if millions of poor HIV-positive African women of child-bearing age were given the new, more effective drug [that in a separate study was associated with an increased risk of fatal birth defects among babies born to women taking the drug when they conceived]. How many babies might be harmed? On the other hand, if the more effective drug were withheld, how many adult women would suffer health consequences? It has become a complicated equation, calling attention to a larger problem: How do very poor countries balance the health of women with the health of the babies they might bear? … What [the researchers] found were difficult trade-offs. The newer drug would save thousands of women’s lives and halt the spread of HIV to tens of thousands people — but at the cost of fatal brain defects in a few thousand infants…” (Brink, 4/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.